At the 31st Annual AF Symposium in Boston, Johnson & Johnson revealed important new findings on atrial fibrillation. The company showcased eleven abstracts highlighting clinical data for its Pulsed Field Ablation (PFA) and Ultrasound portfolios. These presentations also included product updates designed to improve outcomes for patients living with atrial fibrillation.
Johnson & Johnson emphasized its commitment to evidence-driven innovation. It introduced the updated VARIPULSE Plus Platform, which features automated irrigation flow for enhanced procedural safety. This platform strengthens the portfolio of tools available to electrophysiologists treating atrial fibrillation. Additionally, it streamlines ablation and mapping in a single workflow when combined with the CARTO 3 System.
The company also announced the commercial launch of the NUVISION NAV Ultrasound Catheter. This 4D intracardiac imaging catheter integrates fully with a 3D electroanatomical mapping system. It enhances anatomical visualization and precise navigation during complex electrophysiology procedures. Furthermore, it reduces fluoroscopy exposure and minimizes catheter manipulation.
“Evidence-based innovation drives how we advance arrhythmia care,” said Michael Bodner, Company Group Chair, Electrophysiology & Neurovascular, MedTech at Johnson & Johnson. He explained that the symposium updates demonstrate the company’s strength in electrophysiology, which supports atrial fibrillation ablation strategies effectively.
Several key studies presented at the symposium addressed both safety and procedural outcomes for atrial fibrillation treatment. One late-breaking presentation focused on pulsed field ablation using a large-tip focal catheter combined with 3D mapping integration from the OMNY-AF pilot study. Additional poster presentations covered reduced neurovascular events and acute safety profiles for PFA catheters used in paroxysmal and persistent atrial fibrillation. Others addressed irrigation flow optimization during ablation procedures.
The data also demonstrated the role of 4D intracardiac echo with the NUVISION NAV catheter versus conventional transesophageal echocardiography. These findings showed their utility for guidance during left atrial appendage occlusion procedures. Advanced imaging proves valuable for managing atrial fibrillation more safely and efficiently.
In addition to scientific updates, Johnson & Johnson conducted a comprehensive educational program. Hands-on sessions using the CARTO 3 System allowed attendees to experience the VARIPULSE Plus Platform. Participants also explored the next-generation NUVISION NAV Ultrasound Catheter in simulated procedural settings.
Across its MedTech cardiovascular portfolio, Johnson & Johnson addresses complex health challenges with advanced mapping, navigation, and ablation technologies. These tools target heart failure, coronary artery disease, stroke, and atrial fibrillation, a condition causing irregular heart rhythms with heightened risks of stroke and heart failure.
The company’s integrated solutions aim to elevate care standards globally for electrophysiology patients. Combining miniaturized technology with procedural insight, Johnson & Johnson fosters innovation and real-world evidence generation. These efforts equip clinicians to treat atrial fibrillation effectively and reliably.
Industry observers note that these developments occur amid competition in atrial fibrillation treatment technologies. Several competitors are launching new imaging systems and pulsed field ablation platforms. Nevertheless, Johnson & Johnson possesses a well-rounded operational model (with a large amount of clinical data), which consistently leads them to be considered an industry leader.
In the coming years, they intend to continue to build upon this foundation of science. Current trials and upcoming iterations will include additional improvements for enhancing safety during ablation procedures. Additionally, they will work to develop even more therapies available to the patients who suffer from Atrial Fibrillation.
At the AF Symposium, the variety of work presented illustrates how AF patient care is being transformed through innovation, clinical data, and physician education, creating superior outcomes for patients suffering from one of the most common cardiac rhythm disorders throughout the world.
